| 2023-05-22 |
详情>>
股本变动：
变动后总股本320.15万股
|
| 2023-05-22 |
详情>>
业绩披露：
2023年一季报每股收益-2.72美元,归母净利润-870万美元,同比去年增长26.39%
|
| 2023-04-17 |
详情>>
业绩披露：
2022年年报每股收益-21.32美元,归母净利润-5718.5万美元,同比去年增长-15.64%
|
| 2023-04-17 |
详情>>
业绩披露：
2020年年报每股收益-135.23美元,归母净利润-6948.4万美元,同比去年增长16.05%
|
| 2023-03-27 |
复牌提示：
2023-03-27 09:35:51 停牌，复牌日期 2023-03-27 09:40:51
|
| 2023-01-29 |
详情>>
内部人交易：
Schroeder Theodore R等共交易2笔
|
| 2022-11-10 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-13.55美元,归母净利润-3440.7万美元,同比去年增长5.44%
|
| 2022-11-10 |
财报披露：
美东时间 2022-11-10 盘后发布财报
|
| 2022-09-16 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2022-08-03 |
详情>>
业绩披露：
2022年中报每股收益-0.38美元,归母净利润-2289.3万美元,同比去年增长11.04%
|
| 2022-07-11 |
股东大会：
将于2022-08-11召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the nine director nominees named in this proxy statement to our board of directors to serve until the Company’s 2023 Annual General Meeting of Shareholders;
2.To ratify, in a non-binding advisory vote, the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent registered public accounting firm’s remuneration;
3.To approve an amendment to the Nabriva Therapeutics plc 2020 Share Incentive Plan, as amended, to increase the number of ordinary shares authorized for issuance thereunder;
4.To approve the Company’s named executive officer compensation on an advisory basis;
5.To approve, subject to and conditional upon the board of directors determining, in its sole discretion, that a reverse stock split is necessary for the Company to comply with the minimum $1.00 per share requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), a reverse stock split (i.e., a consolidation of share capital under Irish law) whereby such number of authorized and unissued and authorized and issued shares in the capital of the Company as the board of directors of the Company may determine that is not less than 10 ordinary shares and not more than 25 ordinary shares be consolidated into one ordinary share of such nominal value as is proportionate to the determined consolidation ratio, which nominal value shall not be less than $0.10 each (nominal value) and not more than $0.25 each (nominal value), and the subsequent reduction in the nominal value of the ordinary shares in the authorized and unissued and authorized and issued share capital of the Company from the aforementioned nominal value (as reflects the share consolidation ratio chosen by the board of directors) to $0.01 each;
6.To transact such other business as may properly come before the AGM or any adjournment or postponement thereof.
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.2美元,归母净利润-1181.9万美元,同比去年增长15.46%
|
| 2022-03-29 |
详情>>
业绩披露：
2021年年报每股收益-1.14美元,归母净利润-4945万美元,同比去年增长28.83%
|
| 2022-03-29 |
详情>>
业绩披露：
2019年年报每股收益-11.15美元,归母净利润-8276.4万美元,同比去年增长27.89%
|
| 2021-11-22 |
股东大会：
将于2021-12-22召开股东大会
会议内容 ▼▲
- 1.To grant the board of directors authority under Irish law to allot and issue ordinary shares (including rights to acquire ordinary shares) for cash without first offering those ordinary shares to existing shareholders pursuant to the statutory pre-emption right that would otherwise apply (Proposal 1).
|
| 2021-11-09 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.93美元,归母净利润-3638.7万美元,同比去年增长29.55%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-05 |
详情>>
业绩披露：
2021年中报每股收益-0.77美元,归母净利润-2573.5万美元,同比去年增长33.50%
|
| 2021-07-01 |
股东大会：
将于2021-07-28召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the nine director nominees named in this proxy statement to our board of directors to serve until the Company’s 2022 Annual General Meeting of Shareholders;
2.To ratify, in a non-binding advisory vote, the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent registered public accounting firm’s remuneration;
3.To approve an increase in the authorized share capital of the Company from US$2,000,000 and 25,000 to US$4,000,000 and 25,000 by the creation of an additional 200,000,000 ordinary shares, which proposal we refer to as the authorized share capital increase proposal;
4.If the authorized share capital increase proposal (Proposal 3) is approved, to grant the board of directors an updated authority under Irish law to allot and issue shares, or other securities convertible into or exercisable or exchangeable for shares, which proposal we refer to as the directors’ allotment authority proposal;
5.If the directors’ allotment authority proposal (Proposal 4) is approved, to grant the board of directors an updated authority under Irish law to issue ordinary shares, or other securities convertible into or exercisable or exchangeable for ordinary shares, for cash without first offering those ordinary shares, or other securities convertible into or exercisable or exchangeable for ordinary shares, to existing shareholders under pre-emptive rights that would otherwise apply to the issuance, which proposal we refer to as the pre-emption rights dis-application proposal;
6.To hold an advisory vote on named executive officer compensation;
7.To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation;
8.To transact such other business as may properly come before the AGM or any adjournment or postponement thereof.
|
| 2021-05-06 |
详情>>
业绩披露：
2021年一季报每股收益-0.53美元,归母净利润-1398.1万美元,同比去年增长39.89%
|
| 2020-12-02 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2020-06-25 |
股东大会：
将于2020-07-29召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the seven director nominees named in this proxy statement to our board of directors to serve until the Company's 2021 Annual General Meeting of Shareholders;
2.To ratify, in a non-binding advisory vote, the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent registered public accounting firm's remuneration;
3.To approve the adoption of the Company's 2020 Share Incentive Plan, as amended;
4.To approve, subject to and conditional upon the board of directors determining, in its sole discretion, that a reverse stock split is necessary for the Company to comply with the minimum $1.00 per share requirement pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Rule"), a reverse stock split (i.e., a consolidation of share capital under Irish law) whereby every 10 ordinary shares of $0.01 (nominal value) each in the authorized and unissued and authorized and issued share capital of the Company be consolidated into 1 ordinary share of $0.10 (nominal value) each, and the subsequent reduction in the nominal value of the ordinary shares in the authorized and unissued and authorized and issued share capital of the Company from $0.10 each to $0.01 each;
5.To transact such other business as may properly come before the AGM or any adjournment or postponement thereof.
|
| 2019-06-14 |
股东大会：
将于2019-07-31召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the eight director nominees named in this proxy statement to our board of directors to serve until the Company's 2020 Annual General Meeting of Shareholders;
2.To ratify, in a non-binding advisory vote, the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2019 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent registered public accounting firm's remuneration;
3.To transact such other business as may properly come before the AGM or any adjournment or postponement thereof.
|
| 2018-10-01 |
股东大会：
将于2018-10-31召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with applicable rules of the Nasdaq Global Market, the allotment and issuance of our ordinary shares in settlement of potential milestone payment obligations that may become payable by us in the future to former security holders of Zavante Therapeutics, Inc. ("Zavante"), which we acquired on July 24, 2018, pursuant to our Agreement and Plan of Merger, dated as of July 23, 2018, with Zavante;
2.To transact such other business as may properly come before the EGM or any adjournment or postponement thereof.
|
| 2018-06-19 |
股东大会：
将于2018-08-01召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolutions, the seven director nominees named in this proxy statement to our board of directors to serve until the Company's 2019 Annual General Meeting of Shareholders;
2.To ratify, in a non-binding advisory vote, the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to set the independent registered public accounting firm's remuneration;
3.To approve the adoption of the Company's 2018 Employee Share Purchase Plan;
4.To approve the adoption of an amendment to the Company's 2017 Share Incentive Plan;
5.To receive and consider the Company's Irish Statutory Financial Statements for the fiscal year ended December 31, 2017 and the reports of the directors and auditors thereon, and to review the affairs of the Company;
6.To transact such other business as may properly come before the AGM or any adjournment or postponement thereof.
|
| 2017-08-18 |
股东大会：
将于2017-09-15召开股东大会
会议内容 ▼▲
- 1.To elect, by separate resolution, the eight director nominees named in this proxy statement to our board of directors to serve until the 2018 Annual General Meeting of Shareholders;
2.To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.To approve the adoption of the Company's 2017 Share Incentive Plan;
4.To transact such other business as may properly come before the EGM or any adjournment or postponement thereof.
|
| 2016-08-29 |
股东大会：
将于2016-08-25召开股东大会
会议内容 ▼▲
- 1. Presentation of the acknowledged (festgestellt) annual financial statement as of 31 December 2015 as well as the management report and the report of the supervisory board in accordance with section 96 Austrian Stock Corporation Act for the business year 2015.
2. Distribution of profits from the business year 2015.
3. Resolution on the release of the members of the supervisory board from responsibility for the business year 2015.
4. Resolution on the release of the members of the management board from responsibility for the business year 2015.
5. Appointment of auditors for the business year 2016.
6. Resolution on
a. the revocation of the authorizations of the management board pursuant to section 4 of the company’s articles of association to increase the company’s registered share capital, subject to the approval of the supervisory board, by the aggregate amount of EUR 384,735 by way of issuing 384,735 no-par value registered shares against contribution in cash or in-kind;
b. the authorization of the management board to increase the company’s registered share capital within a period of five years from registration of the respective amendment of the company’s articles of association in the commercial register, subject to the approval of the supervisory board, by up to EUR 918,033 by way of issuing up to 918,033 new no-par value registered shares against contribution in cash or in-kind in full or in part, to exclude the shareholders’ subscription rights, and to determine the issue price which may not be below the proportionate amount per share in the company’s registered share capital, as well as issuance conditions in agreement with the supervisory board (Authorized Capital 2016);
c. the authorization of the supervisory board to resolve on the amendments of the company’s articles of association resulting from the issuance of new shares out of Authorized Capital 2016.
7. Resolution on
a. the authorization of the management board to increase the company’s registered share capital within a period of five years from registration of the respective amendment of the company’s articles of association in the commercial register, subject to the approval of the supervisory board, by up to EUR 146,129 by way of issuing up to 146,129 new no-par value registered shares against contribution in cash or in-kind in full or in part for the purposes to service the stock options granted to selected employees or members of the management board and the supervisory board and external consultants of the company under the existing stock option plan 2015, as amended (Authorized Capital 2016 — SOP);
b. the exclusion of subscription rights of current shareholders relating to Authorized Capital 2016 — SOP;
c. the authorization of the supervisory board to resolve on the amendments of the company’s articles of association resulting from the issuance of new shares out of the Authorized Capital 2016 — SOP.
8. Resolution on
a. the revocation of an aggregate amount of EUR 83,657 conditional capital pursuant to section 4 of the company’s current articles of association to conditionally increase the company’s registered share capital by issuing up to 83,657 no-par value registered shares upon execution of granted stock option rights;
b. the conditional increase of the company’s registered share capital pursuant to section 159 para 2 item 3 Austrian Stock Corporation Act by up to EUR 197,770 by issuing up to 197,770 new no-par value registered shares to service the stock options granted to selected employees or members of the management board and the supervisory board and external consultants of the company under the existing stock option plan 2015, as amended (Conditional Capital 2016 — SOP);
c. the exclusion of subscription rights of current shareholders relating to Conditional Capital 2016 — SOP;
d. the authorization of the supervisory board to resolve on the amendments of the company’s articles of association resulting from the issuance of new shares out of Conditional Capital 2016 — SOP.
9. Resolution on
a. the revocation of an aggregate amount of EUR 423,074 conditional capital pursuant to section 4 of the company’s current articles of association to conditionally increase the company’s registered share capital by issuing up to 423,074 no-par value registered shares to be issued to holders of convertible bonds;
b. the conditional increase of the company’s registered share capital pursuant to section 159 para 2 item 1 Austrian Stock Corporation Act by up to EUR 704,162 by issuing up to 704,162 new no-par value registered shares to be issued to holders of convertible bonds (Conditional Capital 2016 — Convertible Bonds);
c. the exclusion of subscription rights of current shareholders relating to Conditional Capital 2016 — Convertible Bonds.
d. the authorization of the supervisory board to resolve on the amendments of the company’s articles of association resulting from the issuance of new shares out of Conditional Capital 2016 — Convertible Bonds.
10. Resolution on the authorization of the management board to issue convertible bonds providing for a right to conversion and/or subscription of an aggregate amount of up to 704,162 new no-par value registered shares within a period of five years after the date of this resolution (Convertible Bonds 2016).
11. Resolution on the approval of the supervisory board compensation policy.
12. Resolution on the amendments of the stock option plan 2015, resolved upon in the general meeting on 2 April 2015, as amended in the general meeting on 30 June 2015.
13. Resolution on amendments to the company’s articles of association.
14. Election of members of the supervisory board.
|